Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapy

This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.

Novartis: pipeline will generate 60 filings in three years

Novartis: pipeline will generate 60 filings in three years

Mayzent is a follow-up to Novartis’blockbuster MS therapy Gilenya (fingolimod), which brought in $2.5bn in the first nine months of the year and is facing the threat of ... Already active in this area with its lymphoma and leukaemia CAR-T therapy

Latest news

  • Celgene to launch five new products through to 2020 Celgene to launch five new products through to 2020

    Celgene to launch five new products through to 2020. Two of which are CAR-T candidates. ... myelofibrosis, thalassaemia therapy luspatercept, and CAR-T candidates lisocabtagene maraleucel (liso-cel) for lymphoma and bb2121 for multiple myeloma.

  • Novartis buys cancer specialist Endocyte for $2.1bn

    It’s worth pointing out that buying Endocyte also gives Novartis an additional platform in CAR-T cancer immunotherapy to complement its current assets, including already-marketed therapy Kymriah (tisagenlecleucel) for ... Endocyte has developed an

  • Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

    Kite was sold on to Gilead Sciences, along with FDA-approved CAR-T therapy Yescarta, one of the first two of the groundbreaking cell therapies to reach the market, just behind ... If all goes well for UCART19, it could not only rival Novartis' CAR-T

  • Gilead strikes deal with NHS England on CAR-T Yescarta

    NHS England has agreed a market access deal with Gilead for its groundbreaking CAR-T therapy Yescarta, and is claiming it to be the first European deal. ... It is likely that we are only beginning to see the benefits that CAR-T therapy can bring.

  • CRUK forges £30m ‘post-Brexit’ R&D alliance CRUK forges £30m ‘post-Brexit’ R&D alliance

    Another £5m project led by CRUK’s Beatson Institute in Glasgow – ARCCelerate – will concentrate on finding new ways to deliver personalised therapy for bowel cancers. ... In Italy, the University of Milan-Bicocca will run the £4.5m INCAR project

More from news
Approximately 4 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Bluebird Bio's chief executive Nick Leschly. Cell and gene therapy made the transition from an interesting but unproven science to medical reality in 2017, with two ‘living medicine’CAR-T ... Its fourth pipeline candidate is the multiple myeloma

  • No incentive for a cure No incentive for a cure

    These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83% remission rate in children and young adults with B-cell precursor acute lymphoblastic leukaemia. ... One of the biggest questions with a curative

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    CAR-T cell therapy for children with B-cell ALL. ... costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • The rise of real-world evidence The rise of real-world evidence

    Novartis secured such an outcome-based model for its CAR-T therapy Kymriah. ... Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.

  • Deal Watch January 2018

    Having terminated the development of its lead CAR-T therapy, JCAR015, early last year after several patient deaths in a phase II clinical trial in relapsed/refractory B-cell acute lymphoblastic ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’ s Yescarta in October.

  • Innovation in pharma: the highs and lows of the current healthcare economy

    Gene therapies often require a ‘ one-time only’ treatment offering life-changing potential to patients with conditions where currently there may be no available therapy at all, for instance, in rare ... Also in cancers: chimeric antigen receptor T

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
ben.quarless@publicishealth.com

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics